Floatz logo

Delpacibart Zotadirsen

Muscular Dystrophy, Duchenne

Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

56 Active assets in the Muscular Dystrophy, Duchenne cohort.

Asset / SponsorPhaseRating
Viltolarsen
NS Pharma, Inc.
Phase 4BBB
Aoc 1044
Avidity Biosciences, Inc.
Phase 3BB
Delandistrogene Moxeparvovec
Sarepta Therapeutics, Inc.
Phase 3BB
Golodirsen
Rare Disease Research, LLC
Phase 4BB
Glutamine
Assistance Publique - Hôpitaux de Paris
Phase 3BB

View all 50 →

Same molecule, other indications

Delpacibart Zotadirsen is also rated in:

musculoskeletal system disorderDormant
D
Indicative ·
30 / 100
View asset →
neuromuscular diseaseDormant
D
Indicative ·
30 / 100
View asset →
muscular atrophyDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →